TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12711184

Group type: EXPERIMENTAL
Intervention: Oseltamivir administered via Enterion capsule (150 mg) to the stomach
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oseltamivir administered via Enterion capsule (150 mg) to the proximal small bowel
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oseltamivir administered via Enterion capsule (150 mg) to the distal small bowel
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oseltamivir administered via Enterion capsule (150 mg) to the ascending colon
Number of subjects: 9
Study: 9857539

Group type: EXPERIMENTAL
Intervention: Ultrasound examination of preepiglottic space
Number of subjects: 73

Group type: COMPARATOR
Intervention: CT examination of preepiglottic space
Number of subjects: 73
Study: 7835241

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS) for insulinoma
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Somatostatin receptor scintigraphy (SRS) for insulinoma
Number of subjects: 13

Group type: COMPARATOR
Intervention: CT, US, and MRI together for insulinoma
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS) for gastrinoma
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Somatostatin receptor scintigraphy (SRS) for gastrinoma
Number of subjects: 13

Group type: COMPARATOR
Intervention: CT, US, and MRI together for gastrinoma
Number of subjects: 13
Study: 1977432

Group type: EXPERIMENTAL
Intervention: Dopexamine 4 micrograms kg‐1 min‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dopamine 5 micrograms kg‐1 min‐1
Number of subjects: 20
Study: 307546

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan plus carbidopa
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo I
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo II
Number of subjects: 3

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 3
Study: 31589276

Group type: EXPERIMENTAL
Intervention: Free distribution of essential medicines (n = 395)
Number of subjects: 786

Group type: COMPARATOR
Intervention: Usual access to medicines (n = 391)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Free distribution of essential medicines
Number of subjects: 786
Study: 28432326

Group type: EXPERIMENTAL
Intervention: T stem cell memory (TSCM) cells identified by phenotypic markers of CD4+ T cells; subsets characterized by IL-2/IL-15 receptors and APOBEC3G anti-viral restriction factors; no specific dosage or duration mentioned.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endogenous HSP70 activation of TSCM and innate immunity pathways; no specific dosage or duration mentioned.
Number of subjects: 0
Study: 25464418

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 1498
Study: 23549382

Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide (n = 31)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthesia with 30% oxygen (n = 30)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthesia with 80% oxygen (n = 30)
Number of subjects: 91
Study: 21323294

Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty (THA) after thorough debridement
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty (THA)
Number of subjects: 8
Study: 19804459

Group type: EXPERIMENTAL
Intervention: Smoking characters in a movie segment
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-smoking characters in a movie segment
Number of subjects: 65
Study: 16706298

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus Self‐Etch
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond and Optibond Solo Plus Self‐Etch
Number of subjects: 70
Study: 15656396

Group type: EXPERIMENTAL
Intervention: Emoxipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reamberine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mexidole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11728760

Group type: EXPERIMENTAL
Intervention: Activated charcoal (AC) mixed with regular cola
Number of subjects: 15

Group type: COMPARATOR
Intervention: Activated charcoal (AC) mixed with diet cola
Number of subjects: 15
Study: 9226208

Group type: EXPERIMENTAL
Intervention: Liothyronine (L-T3)
Number of subjects: 17
Study: 8429321

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin treatment (IVIg) for 5 consecutive days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin treatment (IVIg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Electrophysiological studies
Number of subjects: 28
Study: 3618665

Group type: EXPERIMENTAL
Intervention: Maternal ambulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 100
Study: 31808538

Group type: EXPERIMENTAL
Intervention: Serratus plane block
Number of subjects: 94

Group type: COMPARATOR
Intervention: Systemic analgesics (control group)
Number of subjects: 94
Study: 31203245

Group type: EXPERIMENTAL
Intervention: Salt-reduction behaviours (SRB score) intervention
Number of subjects: 603

Group type: COMPARATOR
Intervention: Social support from family members
Number of subjects: 603

Group type: COMPARATOR
Intervention: Class size and friendship connections
Number of subjects: 603

Group type: COMPARATOR
Intervention: Teacher intervention programme attendance
Number of subjects: 603
Study: 27393218

Group type: EXPERIMENTAL
Intervention: Caphosol mouthwash plus standard oral care
Number of subjects: 215

Group type: COMPARATOR
Intervention: Standard oral care alone
Number of subjects: 215
Study: 25591439

Group type: EXPERIMENTAL
Intervention: Dialysate APR (2.5% glucose-based peritoneal dialysis solution)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ringer solution APR
Number of subjects: 96

Group type: COMPARATOR
Intervention: Shock group (conventional intravenous resuscitation)
Number of subjects: 96
Study: 23151341

Group type: EXPERIMENTAL
Intervention: Q-1000 (1000 mg/d of quercetin, 250 mg/d of vitamin C and 10 mg/d of niacin)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Q-500 (500 mg/d of quercetin, 125 mg/d of vitamin C and 5 mg/d of niacin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 22183994

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 14
Study: 19328244

Group type: EXPERIMENTAL
Intervention: Enhanced nurse case management (NCM)
Number of subjects: 549
Study: 18180897

Group type: EXPERIMENTAL
Intervention: Graded therapy featuring integrative traditional Chinese and Western medicine including 1.8 g of Xuefuda orally once per day, intravenous dripping of 250 mL of hemostasis mixture twice a day, 1.2 g of clindamycin per day for stage I; Kangyanling intra-articular injection for stage II-III; 25 mg of sodium hyaluronate for stage IV.
Number of subjects: 40
Study: 15016940

Group type: EXPERIMENTAL
Intervention: Chest clinic follow up (intervention group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Regular primary care (control group)
Number of subjects: 25
Study: 11171827

Group type: EXPERIMENTAL
Intervention: Hypermethylation of the CDH1 promoter region in UCACRC
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hypermethylation of the CDH1 promoter region in SCRC
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Correlation of hypermethylation with E-cadherin expression
Number of subjects: 28
Study: 9869552

Group type: EXPERIMENTAL
Intervention: Blood volume determination and plasma catecholamines measurement during episodes
Number of subjects: 21
Study: 9138872

Group type: EXPERIMENTAL
Intervention: Laparoscopic Pomeroy tubal ligation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard coagulation
Number of subjects: 57
Study: 2574594

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg twice daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 1062298

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate
Number of subjects: 15

Group type: COMPARATOR
Intervention: H2O2
Number of subjects: 15
Study: 30962268

Group type: EXPERIMENTAL
Intervention: Endotoxin (Escherichia coli lipopolysaccharide, LPS, 0.8 ng/kg body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 20
Study: 27770397

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation therapy (ADT) for 6 months
Number of subjects: 77

Group type: COMPARATOR
Intervention: Continuous androgen deprivation therapy (ADT) for 36 months
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Quality of life assessments using QLQ-C30 and QLQ PR-25
Number of subjects: 77
Study: 25542824

Group type: EXPERIMENTAL
Intervention: Cell phone intervention (CPI)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 350
Study: 23701149

Group type: EXPERIMENTAL
Intervention: 200 mcg vaginal misoprostol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 400 mcg vaginal misoprostol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no misoprostol)
Number of subjects: 60
Study: 21569343

Group type: EXPERIMENTAL
Intervention: Aerobic fitness (20 m shuttle run)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Agility test (obstacle course)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Baseline aerobic fitness
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Baseline dynamic balance (balance beam)
Number of subjects: 245
Study: 18094221

Group type: EXPERIMENTAL
Intervention: 600 mg rifampin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16921044

Group type: EXPERIMENTAL
Intervention: No systemic therapy
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 313
Study: 12547376

Group type: EXPERIMENTAL
Intervention: Applied Tension (AT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control condition (no AT)
Number of subjects: 44
Study: 11016021

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LA) 320 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aspirin 320 mg
Number of subjects: 10
Study: 9367285

Group type: EXPERIMENTAL
Intervention: CEx (Cycle Ergometer Exercise at 23 degrees C)
Number of subjects: 11

Group type: COMPARATOR
Intervention: CS (Seated Control at 23 degrees C)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: HEx (Heat Exercise at 40 degrees C)
Number of subjects: 11

Group type: COMPARATOR
Intervention: HS (Heat Seated Control at 40 degrees C)
Number of subjects: 11
Study: 8263981

Group type: EXPERIMENTAL
Intervention: Cryopreserved cultured allograft dressings (CCAD)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Tulle‐gras dressings
Number of subjects: 5
Study: 2939219

Group type: EXPERIMENTAL
Intervention: Ketanserin (K), 40 mg twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Metoprolol (M), 100 mg twice daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ketanserin (K)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Metoprolol (M)
Number of subjects: 32
Study: 30027406

Group type: EXPERIMENTAL
Intervention: Hexanic extract of Serenoa repens (HESr) 320 mg/day
Number of subjects: 97

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 97
Study: 29971969

Group type: EXPERIMENTAL
Intervention: Low-frequency electrical muscle stimulation (LF‐EMS)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham (skin level stimulation only)
Number of subjects: 35
Study: 26883089

Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde and Capsaicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24939648

Group type: EXPERIMENTAL
Intervention: Continuous oxygen supplementation for 72 hours
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen supplementation for three nights
Number of subjects: 8000

Group type: COMPARATOR
Intervention: No routine oxygen supplementation
Number of subjects: 8000
Study: 23001689

Group type: EXPERIMENTAL
Intervention: Multi-component intervention promoting breastfeeding, reducing sugar-sweetened beverage consumption, appropriate timing of healthy solid foods introduction, and counseling to reduce sedentary lifestyles
Number of subjects: 577

Group type: COMPARATOR
Intervention: Comparison condition (control group)
Number of subjects: 577
Study: 20684401

Group type: EXPERIMENTAL
Intervention: Various strategies to avoid physician's inertia and combat patient's non-compliance, including titration, rescue medications, and self-monitoring.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pill count for compliance verification during the placebo run-in period.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical analysis restricted to individuals adhering to the study protocol (per protocol analysis).
Number of subjects: 0
Study: 17432675

Group type: EXPERIMENTAL
Intervention: Acupuncture group with 'Jin's three‐needling'
Number of subjects: 58

Group type: COMPARATOR
Intervention: Medication group treated with anti‐anxiety drugs
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 15523456

Group type: EXPERIMENTAL
Intervention: Contact diode laser (CDL) tonsillectomy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Monopolar cautery (MPC) tonsillectomy
Number of subjects: 58
Study: 11305823

Group type: EXPERIMENTAL
Intervention: Dopexamine infusion (0.5 - 2 microg x kg(‐1) x min(‐1))
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (placebo infusion)
Number of subjects: 24
Study: 9236827

Group type: EXPERIMENTAL
Intervention: Pyrethroid (permethrin and lambdacyhalothrin) impregnated bednets with community education programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based impregnation programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational methods and promotion of dark-colour nets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Impregnation of bednets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pretesting of soaking capacity of different net materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instructions for impregnation procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of very cheap thin net materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring of side-effects of last-generation pyrethroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Further studies on protective efficacy of bednets
Number of subjects: 0
Study: 7937768

Group type: EXPERIMENTAL
Intervention: Initial glucose step at 3.61 mmol/liter
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Initial glucose step at 4.16 mmol/liter
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Initial glucose step at 3.05 mmol/liter
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Final day glucose clamp starting at 4.16 mmol/liter
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Final day glucose concentration of 2.50 mmol/liter
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Final day glucose steps
Number of subjects: 12
Study: 2894232

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg twice daily
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once daily
Number of subjects: 2435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: Aspirin (both doses)
Number of subjects: 2435
Study: 30484837

Group type: EXPERIMENTAL
Intervention: sacubitril-valsartan
Number of subjects: 8399

Group type: COMPARATOR
Intervention: ACEI
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 8399

Group type: COMPARATOR
Intervention: β-blockers
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Mineralocorticoid antagonists
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy
Number of subjects: 8399
Study: 28147451

Group type: EXPERIMENTAL
Intervention: 12 Alexander lessons over 12 weeks and usual care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 26200278

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m every 21 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topotecan 1.5 mg/m on days 1-5 every 21 days
Number of subjects: 0
Study: 22610788

Group type: EXPERIMENTAL
Intervention: sGC-RT (sequential CRT with gemcitabine and cisplatin)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Con-RT (cisplatin-based concurrent chemoradiotherapy plus adjuvant PF chemotherapy)
Number of subjects: 240
Study: 21143244

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Number of subjects: 79

Group type: COMPARATOR
Intervention: No-stress control condition
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups (Trier Social Stress Test and No-stress control)
Number of subjects: 79
Study: 18212696

Group type: EXPERIMENTAL
Intervention: Milrinone (0.5 microg/kg/min infusion)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Adrenaline (0.01-0.02 microg/kg/min)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (no inotropes)
Number of subjects: 77
Study: 17021320

Group type: EXPERIMENTAL
Intervention: AIC vaccine
Number of subjects: 25
Study: 12554027

Group type: EXPERIMENTAL
Intervention: Moderate- or high-intensity counseling interventions including interactive health communication tools
Number of subjects: 21

Group type: COMPARATOR
Intervention: Brief counseling by primary care providers
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: More-intensive interventions
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Interactive health communications (computer-generated telephone or mail messages)
Number of subjects: 21
Study: 10850607

Group type: EXPERIMENTAL
Intervention: fentanyl, N2O plus halothane
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: fentanyl, N2O plus propofol
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: fentanyl, N2O plus isoflurane
Number of subjects: 140

Group type: COMPARATOR
Intervention: fentanyl and N2O (control group)
Number of subjects: 140
Study: 9085959

Group type: EXPERIMENTAL
Intervention: Tourniquet kept inflated for 10 min after I.A. injection of morphine (5 mg in 25 mL saline)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tourniquet deflated immediately after I.A. injection of morphine (5 mg in 25 mL saline)
Number of subjects: 40
Study: 1492861

Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (DHEC) 1.5 mg/d
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (DHEC) 3 mg/d
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (DHEC) 6 mg/d
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 4080903

Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 ml of pure alcohol per kg body weight)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31208470

Group type: EXPERIMENTAL
Intervention: Auricular acupressure treatment once per week for 4 weeks and calcipotriol betamethasone ointment once daily for 4 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Calcipotriol betamethasone ointment once daily for 4 weeks
Number of subjects: 180
Study: 29369178

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 30592829

Group type: EXPERIMENTAL
Intervention: Balneo-physiotherapeutic procedures including venous laser light, gradient magnetic field, dry carbon dioxide baths, and baths with horse chestnut.
Number of subjects: 0
Study: 25850997

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: aPL positive IgG spiking of PNP
Number of subjects: 52
Study: 23110952

Group type: EXPERIMENTAL
Intervention: Bromocriptine (Bc; 16 mg/heifer)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Acyline (Ac; 3 μg/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bromocriptine and acyline combined (BcAc)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (Ct)
Number of subjects: 28
Study: 20429818

Group type: EXPERIMENTAL
Intervention: Brimonidine/timolol fixed combination (BrTFC) twice daily for 6 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Dorzolamide/timolol fixed combination (DTFC) twice daily for 6 weeks
Number of subjects: 25
Study: 18373654

Group type: EXPERIMENTAL
Intervention: Baclofen 10 mg four times per day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15661416

Group type: EXPERIMENTAL
Intervention: Artificial urinary sphincter implantation (AUS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Endourethral macroplastique injection
Number of subjects: 45
Study: 12442916

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (67 mg/m2/week)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Every 3 weeks paclitaxel (72.7 mg/m2/week)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Intravenous steroids
Number of subjects: 208

Group type: COMPARATOR
Intervention: Oral steroids
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel
Number of subjects: 208
Study: 10523429

Group type: EXPERIMENTAL
Intervention: Moderate emphasis on transference analysis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Minor or no use of transference analysis
Number of subjects: 60
Study: 8549570

Group type: EXPERIMENTAL
Intervention: Swim-bench exercise (SB)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Arm stroke (AS)
Number of subjects: 6
Study: 1777370

Group type: EXPERIMENTAL
Intervention: Enzyme-inducing anticonvulsants (carbamazepine, phenobarbitone or phenytoin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 0
Study: 6094457

Group type: EXPERIMENTAL
Intervention: Cefotaxime (50 mg/kg/im route)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 10-day antibiotic therapy
Number of subjects: 37